Overview

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA < 6 x106 IU/mL Duration of Subjects will be treated for 8 weeks and followed for 24 weeks post- Treatment: treatment

Phase:

Phase 2

Details

Lead Sponsor:

Peter J. Ruane, M.D., Inc.

Treatments:

Ledipasvir
Ledipasvir, sofosbuvir drug combination
Sofosbuvir